JP2021514661A5 - - Google Patents
Info
- Publication number
- JP2021514661A5 JP2021514661A5 JP2020546407A JP2020546407A JP2021514661A5 JP 2021514661 A5 JP2021514661 A5 JP 2021514661A5 JP 2020546407 A JP2020546407 A JP 2020546407A JP 2020546407 A JP2020546407 A JP 2020546407A JP 2021514661 A5 JP2021514661 A5 JP 2021514661A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- peptide
- polypeptide
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024035825A JP2024069367A (ja) | 2018-03-05 | 2024-03-08 | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638520P | 2018-03-05 | 2018-03-05 | |
| US62/638,520 | 2018-03-05 | ||
| US201862727156P | 2018-09-05 | 2018-09-05 | |
| US62/727,156 | 2018-09-05 | ||
| PCT/US2019/020685 WO2019173289A1 (en) | 2018-03-05 | 2019-03-05 | Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024035825A Division JP2024069367A (ja) | 2018-03-05 | 2024-03-08 | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514661A JP2021514661A (ja) | 2021-06-17 |
| JP2021514661A5 true JP2021514661A5 (https=) | 2022-03-14 |
Family
ID=67847453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546407A Pending JP2021514661A (ja) | 2018-03-05 | 2019-03-05 | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
| JP2024035825A Pending JP2024069367A (ja) | 2018-03-05 | 2024-03-08 | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024035825A Pending JP2024069367A (ja) | 2018-03-05 | 2024-03-08 | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12365714B2 (https=) |
| EP (1) | EP3762407A4 (https=) |
| JP (2) | JP2021514661A (https=) |
| CN (1) | CN112292391A (https=) |
| AU (2) | AU2019232729B2 (https=) |
| BR (1) | BR112020018196A2 (https=) |
| WO (1) | WO2019173289A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| EP4110803A4 (en) * | 2020-02-27 | 2024-03-27 | Icahn School of Medicine at Mount Sinai | VEGFR-3 ACTIVATING AGENTS AND ONCOLYTIC VIRUSES AND THEIR USES FOR THE TREATMENT OF CANCER |
| US20240101630A1 (en) * | 2020-12-18 | 2024-03-28 | Cullinan Amber Corp. | Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof |
| CN113350522B (zh) * | 2021-05-21 | 2022-08-30 | 浙江大学杭州国际科创中心 | 一种铂铜合金/氯离子转运体复合肿瘤治疗制剂及其制备方法、应用 |
| CN116999539A (zh) * | 2022-04-28 | 2023-11-07 | 天津大学 | 结直肠癌免疫治疗药物ifnbcol01 |
| WO2025010111A1 (en) * | 2023-07-05 | 2025-01-09 | Nanotein Technologies, Inc. | Cell signaling complexes and uses thereof |
| US12473529B2 (en) | 2023-07-18 | 2025-11-18 | Nanotein Technologies, Inc. | Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof |
| WO2025245169A1 (en) * | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| US6211159B1 (en) | 1997-04-11 | 2001-04-03 | University Of Toronto | Flagellin gene, FlaC of campylobacter |
| DE69817393T2 (de) | 1997-11-28 | 2004-06-17 | Sumitomo Pharmaceuticals Co., Ltd. | Neue heterozyklische verbindungen |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| ATE316980T1 (de) | 1999-07-21 | 2006-02-15 | Univ Southern California | Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung |
| MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| AU6934600A (en) | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| US7192725B2 (en) | 2000-05-19 | 2007-03-20 | University Of Toronto | Flagellin gene, flaC of Campylobacter |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| US20050037962A1 (en) | 2002-01-18 | 2005-02-17 | Ekker Stephen C. | Syndecans and angiogenesis |
| EP3006043B1 (en) | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
| CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| JP2007526253A (ja) | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| WO2005082941A1 (en) * | 2004-02-27 | 2005-09-09 | The University Of Western Ontario | Bone sialoprotein collagen-binding peptides |
| US8273357B2 (en) | 2004-07-16 | 2012-09-25 | Massachusetts Institute Of Technology | Antigen-carbohydrate conjugates |
| AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| JP4538522B2 (ja) | 2005-11-25 | 2010-09-08 | コーリー ファーマシューティカル ゲーエムベーハー | 免疫刺激性オリゴリボヌクレオチド |
| WO2007073661A1 (fr) * | 2005-12-26 | 2007-07-05 | Yantai Zhenghai Bio-Technology Co., Ltd. | Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee |
| WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
| US20080160024A1 (en) * | 2006-12-07 | 2008-07-03 | Board Of Trustees Of The University Of Arkansas | Inhibition of cancer metastasis |
| AT504685B1 (de) | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
| WO2011060242A2 (en) | 2009-11-13 | 2011-05-19 | Talecris Biotherapeutics, Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| EP2553101A4 (en) | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| US9879062B2 (en) | 2012-07-03 | 2018-01-30 | Ecole Polytechnique Federale De Lausanne | Protein-binding peptide isolated from placenta growth factor |
| MX387323B (es) * | 2014-02-19 | 2025-03-18 | Merck Patent Gmbh | Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer. |
| WO2016054107A1 (en) | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| WO2018057522A1 (en) * | 2016-09-20 | 2018-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
| WO2018184003A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon |
| US11574747B2 (en) * | 2017-04-20 | 2023-02-07 | The University Of Chicago | Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210221864A1 (en) | 2018-08-24 | 2021-07-22 | City Of Hope | Masked cytokine conjugates |
| CN113710229B (zh) * | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
-
2019
- 2019-03-05 AU AU2019232729A patent/AU2019232729B2/en active Active
- 2019-03-05 US US15/733,582 patent/US12365714B2/en active Active
- 2019-03-05 WO PCT/US2019/020685 patent/WO2019173289A1/en not_active Ceased
- 2019-03-05 CN CN201980030391.2A patent/CN112292391A/zh active Pending
- 2019-03-05 BR BR112020018196-0A patent/BR112020018196A2/pt unknown
- 2019-03-05 EP EP19764476.8A patent/EP3762407A4/en active Pending
- 2019-03-05 JP JP2020546407A patent/JP2021514661A/ja active Pending
-
2024
- 2024-03-08 JP JP2024035825A patent/JP2024069367A/ja active Pending
- 2024-11-06 AU AU2024259762A patent/AU2024259762A1/en active Pending
-
2025
- 2025-06-25 US US19/249,789 patent/US20260049115A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514661A5 (https=) | ||
| Fallon et al. | The immunocytokine NHS-IL12 as a potential cancer therapeutic | |
| US12479918B2 (en) | Plasmid constructs for treating cancer and methods of use | |
| Yu et al. | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma | |
| CA2884707C (en) | Method of treating cancer | |
| JP2020517658A5 (https=) | ||
| US7141550B2 (en) | Intra-tumoral administration of IL-12 encoding nucleic acid molecules | |
| JP2024069367A (ja) | サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 | |
| JP2015521607A (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| Mantooth et al. | Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies | |
| Yang et al. | Synergy of polydopamine nanovaccine and endostar alginate hydrogel for improving antitumor immune responses against colon tumor | |
| Ziffels et al. | Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice | |
| CN118434436A (zh) | 免疫刺激性mrna组合物及其用途 | |
| EP3071220A1 (en) | Preparations and methods for treating a gd2 positive cancer | |
| JP2020531409A (ja) | ホスファチジルセリン標的化融合分子およびそれらの使用方法 | |
| JP7824885B2 (ja) | 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体 | |
| EP2070547B1 (en) | A composition comprising humanized anti-egfr mab h-r3 antibody and type i inf for use in treating cancer | |
| CN116271054A (zh) | 一种工程化髓样细胞及其制备方法和用途 | |
| JP2022066353A (ja) | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 | |
| CN116621966B (zh) | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 | |
| HK40114150A (zh) | 免疫刺激性mrna组合物及其用途 | |
| Niu | Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy | |
| Kelly | The Immunoengineering Toolbox: A Set of Thermoresponsive Biopolymers for Sustained Delivery of Cancer Immunotherapies | |
| US20230302090A1 (en) | Combination therapy for treatment of cancer | |
| CN119462842A (zh) | Cd47、m2型巨噬细胞亲和肽，其制备及应用 |